Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
http://biocytogen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships
Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Deal Watch: Takeda Calls Upon The UK’s F-star Again For Bispecific Candidates
Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Biotechnology
- Drug Discovery Technologies
- Gene Therapy, Cell Therapy
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Eucure Biopharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice